The purpose of this study is to analyze whether the differences between men and women in the frequency of adverse events due to ignoring "Do not do" recommendations in primary care setting are due to biological causes or gender bias.
First, using the Delphi technique, a consensus will be reached on those "Do Not Do" recommendations that should be included in the retrospective analysis study. The selection criteria for these recommendations will be if they are considered to persist in clinical practice in primary care, their relationship with factors associated with sex and gender, and if ignoring the "Do not do" recommendation could cause a serious adverse event. Second, a retrospective cohort study will be carried out in which a random selection of medical records will be reviewed to identify the frequency of adverse events due to ignoring the "Do not do" recommendations previously selected by consensus. Investigators will review a total of 1538 medical records of patients (50% of women) who attended primary care consultation from 1st January 2022 to 31st December 2022. Data source will be the electronic record management system of the autonomous community of Valencia, named ABUCASIS. Adverse events will be identified by using an activation tool used in a previous study (SOBRINA study).
Study Type
OBSERVATIONAL
Enrollment
1,538
A drug prescription or procedure included in 'do not do' recommendations
Miguel Hernández University
Elche, Alicante, Spain
Number of severe adverse events
Number of severe adverse events due to ignore "do not do" recommendations
Time frame: From date of prescription until the date of first documented severe adverse event or date of death from any cause, whichever came first, assessed up to 12 months
Number of female patients who were recommended "do not do"
Number of female patients who were recommended "do not do"
Time frame: From 1st January 2022 to 31 December 2022
Number of male patients who were recommended "do not do"
Number of male patients who were recommended "do not do"
Time frame: From 1st January 2022 to 31 December 2022
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.